Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

BTK Inhibitors, CAR T-Cell Therapies, and JAK Inhibitors Refine Hematologic Oncology Standards

October 21st 2025

Aaron Gerds, MD, MS, discusses the role of BTK inhibitors in CLL, real-world data with CAR T-cell therapies in LBCL, and JAK inhibitors for myelofibrosis.

Dr Jain on Considerations for Sequencing JAK Inhibitors in Myelofibrosis

October 20th 2025

Akriti G. Jain, MD, discusses factors that affect treatment sequencing with JAK inhibitors for the treatment of patients with myelofibrosis.

JAK Inhibitors Persist, While Novel Agents Aim for Disease Modification in Myelofibrosis

October 16th 2025

Aaron Gerds, MD, MS, discusses the clinical applications of each of the FDA-approved JAK inhibitors for the treatment of patients with myelofibrosis.

FDA Grants Orphan Drug Designation to MNV-201 for Myelodysplastic Syndrome

October 16th 2025

MNV-201 has received orphan drug designation from the FDA for use in myelodysplastic syndrome.

Key Areas of Ongoing Research in MDS

October 15th 2025

Guillermo Garcia-Manero, MD, discusses ongoing research to watch in MDS.

Navigating Second-Line Treatment Decisions in Lower-Risk MDS

October 15th 2025

Guillermo Garcia-Manero, MD, discusses second-line treatment decision-making in lower-risk MDS.

Dr Gerds on the Distinct Mechanisms of Action of Approved JAK Inhibitors for Myelofibrosis

October 14th 2025

Aaron T. Gerds, MD, MS, discusses the mechanisms of action of the 4 FDA-approved JAK inhibitors available for the treatment of patients with myelofibrosis.

Dr Jain on Treatment Decision-Making With JAK Inhibitors in Myelofibrosis

October 13th 2025

Akriti G. Jain, MD, details the treatment decision-making of JAK inhibitors for the treatment of patients with myelofibrosis.

Five Under 5: Top Oncology Videos for the Week of 10/5

October 12th 2025

The top 5 OncLive TV videos of the week cover insights in uterine leiomyosarcoma, myelofibrosis, polycythemia vera, breast cancer, and multiple myeloma.

MPN Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025

October 9th 2025

Check out this September recap of OncLive’s coverage of the top news and expert insights in myeloproliferative neoplasms.

Dr Gerds on the Differences Between Available JAK Inhibitors for Myelofibrosis

October 8th 2025

Aaron T. Gerds, MD, MS, discusses the FDA-approved JAK inhibitors for myelofibrosis, as well as where the future of myelofibrosis management may lead.

Dr Gerds on the Importance of Disease-Modifying Therapies in Myelofibrosis

October 7th 2025

Aaron T. Gerds, MD, MS, discusses the limitations of JAK inhibitors and the objectives that the development of next-generation treatments aim to achieve.

Dr Jain on the Role of Ruxolitinib in Polycythemia Vera and Myelofibrosis

October 6th 2025

Akriti G. Jain, MD, discusses the role of ruxolitinib for the treatment with polycythemia vera and myelofibrosis.

FDA Grants Priority Review to Orca-T for Hematologic Malignancies

October 6th 2025

The FDA granted priority review to a biologics license applications seeking the approval of Orca-T for select hematologic malignancies.

Five Under 5: Top Oncology Videos for the Week of 9/28

October 5th 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, and prostate cancer, myelofibrosis.

OncLive Poll Results Spotlight Highly Anticipated Hematology Topics Ahead of ESMO 2025

October 3rd 2025

Multiple myeloma and non-Hodgkin lymphoma emerge as key hematology topics ahead of ESMO 2025, followed by MPNs and T-cell lymphoma.

Dr Daver on Persisting Gaps in the Treatment of Relapsed/Refractory Higher-Risk MDS

October 3rd 2025

Naval G. Daver, MD, discusses persisting gaps in the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes.

Dr Mascarenhas on the Role of Imetelstat in the Myelofibrosis Treatment Paradigm

September 30th 2025

John O. Mascarenhas, MD, discusses the potential role of imetelstat in the treatment of patients with myelofibrosis.

Ropeginterferon Alfa-2b Generates Superior Efficacy vs Anagrelide in High-Risk Essential Thrombocythemia

September 30th 2025

Higher response rates were shown with second-line ropeginterferon alfa-2b compared with anagrelide in patients with high-risk essential thrombocythemia.

Hematologic Oncology Abstracts to Watch at the 2025 ESMO Congress

September 30th 2025

A preview of the hematologic oncology abstracts and presentations to watch at the 2025 ESMO Congress in Berlin.